Business
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement Clinical development plans remain on track across all chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutic
About this update from Trevi Therapeutics, Inc.
[{"type":"image","alt":"Trevi Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Trevi Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":178,"url":"https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bm0hDKDh2VccPo04yMe8oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0OQ--/https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2","width":300,"height":178}},"lazy":false},{"type":"text","content":"Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement","length":224,"tagName":"p"},{"type":"text","content":"Clinical development plans remain on track across all chronic cough indications ","length":79,"tagName":"p"},{"type":"text","content":"Management to host a conference call and webcast today at 4:30 p.m. ET ","length":70,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the quarter ended March 31, 2026, and provided business updates.","length":510,"tagName":"p"},{"type":"text","content":"“We are entering an important phase of execution for Trevi, with study initiations anticipated across our chronic cough programs,” said Jennifer Good, President and CEO of Trevi Therapeutics. “Following a very productive End-of-Phase 2 meeting with the FDA on our lead program in IPF-related chronic cough, we are excited to initiate multiple clinical trials this quarter, including our first Phase 3 in IPF-related chronic cough and our Phase 2b in RCC. With an expected cash runway into 2030, we are well-positioned to execute on our development strategy and advance towards a potential FDA submission in IPF-related chronic cough. We believe successful execution of our strategy would establish Trevi as the leader in providing ...